Seminar: Evolution of the deal-making landscape and key therapeutic areas of the future
När: 24/10/2018 , 10:00 - 12:00
Plats: AstraZeneca BioVentureHub
Adress: Pepparedsleden 5, Mölndal
With the global prescription drug market due to exceed $1.2 trillion by 2024, pricing pressures on healthcare systems are driving innovation and demanding differentiation across all therapeutic and technology areas. A huge rise in collaboration to maximise opportunity and bolster pipelines has driven M&A and BD&L activities over the past 5 years. Deal structures are evolving and Big Pharma is increasingly focused on balancing their level of risk with a need for new opportunities. While the healthcare landscape continues to change and evolve across multiple disease areas, immuno-oncology continues to dominate the larger deal values, but what could be the next therapeutic area in the spotlight?
Adrian Dawkes, Managing Director of PharmaVentures (ex. J&J, Celltech, Acumen Bioscience) and Ashley Cox, Vice President (ex. SmartAnalyst, Inc, Teva, Lundbeck) will introduce what these trends and events will mean for biotech, medtech and diagnostics companies looking to collaborate.
• How can you best prepare to deliver and maximise deal value?
• What therapeutic areas will be the focus of the next wave of Innovation?
• What does it take for a European firm to do deals with fast growing partners in the Far East?
01/10/2021 - 31/10/2021
Sahlgrenska University Hospital